Li-Jiao Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Li-Jiao Yan has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Jian-Ping Liu
Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, China
4 shared publications - Chang-Hao Liang
Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
2 shared publications - Chen Shen
Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
2 shared publications - Mei Han
Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
2 shared publications - Nicola Robinson
Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China; Institute of Health and Social Care, London South Bank University, London SE1 0AA, UK
2 shared publications - Shi-Bing Liang
Clinical Study Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine
2 shared publications
Latest Publications
- Open Access
- 28 January 2025
- Published by Wiley in Health Expectations
- Vol. 28 (1) , e70164
Perceptions and Attitudes of People With Cancer and Diabetes Towards Patient Guidelines: A Mixed Methods Study
Objective: To explore patients' perceptions and attitudes towards patient guidelines (PGs) and to identify specific factors related to PG content, design, presentation, and management that may influence patients' use or adoption of PGs.Methods: An exploratory sequential mixed‐methods design was employed. Initial semi‐structured interviews were conducted with a diverse group of individuals, including people with diabetes or oncology, and clinicians. These interviews were analysed through directed content analysis. Findings from the qualitative study were used to develop a questionnaire. The questionnaire was circulated to patients with diabetes and cancer and asked them to report their awareness, attitudes, and the PG‐related factors influencing their use and adoption of PGs.Results: In total, 25 participants were interviewed qualitatively, and 400 participated in the quantitative survey. Analysis of interviews yielded three themes: perception of PGs, attitude towards PGs, and key PG attributes influencing patients' use or adoption of PG. Qualitative findings indicated limited awareness of PGs, supported quantitatively by only 26.5% of patients being aware of PGs. Attitudes varied, with 73.0% expressing an overall positive attitude towards PG, but only 17.3% preferred PGs for evidence‐based answers and 32.3% favoured them for decision support, citing concerns that general recommendations may not meet individual needs. Participants suggested tailoring recommendations based on subgroups considering age, comorbidity, and weight, explaining why treatments work or don't work in different populations. Eight PG attributes influencing their use or adoption were found: accessibility, identifiability, attractiveness, credibility, usability, timeliness, relevance and simplicity. Lack of credibility was the most frequently mentioned hindrance, with 34.8% identifying unverifiable information as a barrier. Further qualitative and quantitative analyses revealed that medical staff were trusted sources for conveying PGs to patients.Conclusions and Practice Implications: This study underscores the necessity for PGs to acknowledge individual differences and provide recommendations that are more tailored considering age, comorbidities, weight, and other factors influencing decision‐making, ensuring that they address patients' specific needs and support informed decision‐making. Additionally, there was a significant need to improve the dissemination of PGs, using medical staff as key channels to improve patients' use or adoption of PGs.Patient or Public Contribution: In this study, patients were actively involved in several stages. During the development of the interview guide, feedback from two patients, alongside one patient guidelines (PGs) developer and three clinicians, was incorporated to ensure the guide's relevance and comprehensiveness. Patients' insights were integral to refining the interview questions, ensuring they were appropriate and effective. Additionally, the survey questionnaire was pre‐tested among 20 patients using the Think‐Aloud method, which led to significant revisions for better comprehension and response quality. These steps highlight the essential role of patients in shaping the data collection instruments and enhancing the overall quality and relevance of the study.
- 28 January 2025
- Published by Wiley in Health Expectations
- Vol. 28 (1) , e70164
Open AccessPerceptions and Attitudes of People With Cancer and Diabetes Towards Patient Guidelines: A Mixed Methods Study
Objective: To explore patients' perceptions and attitudes towards patient guidelines (PGs) and to identify specific factors related to PG content, design, presentation, and management that may influence patients' use or adoption of PGs.Methods: An exploratory sequential mixed‐methods design was employed. Initial semi‐structured interviews were conducted with a diverse group of individuals, including people with diabetes or oncology, and clinicians. These interviews were analysed through directed content analysis. Findings from the qualitative study were used to develop a questionnaire. The questionnaire was circulated to patients with diabetes and cancer and asked them to report their awareness, attitudes, and the PG‐related factors influencing their use and adoption of PGs.Results: In total, 25 participants were interviewed qualitatively, and 400 participated in the quantitative survey. Analysis of interviews yielded three themes: perception of PGs, attitude towards PGs, and key PG attributes influencing patients' use or adoption of PG. Qualitative findings indicated limited awareness of PGs, supported quantitatively by only 26.5% of patients being aware of PGs. Attitudes varied, with 73.0% expressing an overall positive attitude towards PG, but only 17.3% preferred PGs for evidence‐based answers and 32.3% favoured them for decision support, citing concerns that general recommendations may not meet individual needs. Participants suggested tailoring recommendations based on subgroups considering age, comorbidity, and weight, explaining why treatments work or don't work in different populations. Eight PG attributes influencing their use or adoption were found: accessibility, identifiability, attractiveness, credibility, usability, timeliness, relevance and simplicity. Lack of credibility was the most frequently mentioned hindrance, with 34.8% identifying unverifiable information as a barrier. Further qualitative and quantitative analyses revealed that medical staff were trusted sources for conveying PGs to patients.Conclusions and Practice Implications: This study underscores the necessity for PGs to acknowledge individual differences and provide recommendations that are more tailored considering age, comorbidities, weight, and other factors influencing decision‐making, ensuring that they address patients' specific needs and support informed decision‐making. Additionally, there was a significant need to improve the dissemination of PGs, using medical staff as key channels to improve patients' use or adoption of PGs.Patient or Public Contribution: In this study, patients were actively involved in several stages. During the development of the interview guide, feedback from two patients, alongside one patient guidelines (PGs) developer and three clinicians, was incorporated to ensure the guide's relevance and comprehensiveness. Patients' insights were integral to refining the interview questions, ensuring they were appropriate and effective. Additionally, the survey questionnaire was pre‐tested among 20 patients using the Think‐Aloud method, which led to significant revisions for better comprehension and response quality. These steps highlight the essential role of patients in shaping the data collection instruments and enhancing the overall quality and relevance of the study.
- Open Access
- 8 January 2024
- Published by Taylor & Francis in Renal Failure
- Vol. 46 (1) , 2300302
Fermented Ophiocordyceps sinensis mycelium products for preventing contrast-associated acute kidney injury: a systematic review of randomized controlled trials
To evaluate the efficacy, effectiveness and safety of fermented Ophiocordyceps sinensis mycelium (FOSM) products for preventing contrast-associated acute kidney injury (CA-AKI). Randomized controlled trials were searched from four Chinese and four English electronic databases and three clinical trial registries up to July 2023. Methodological quality was assessed by using the Cochrane risk-of-bias tool 2.0. Risk difference (RD) or risk ratio (RR) and mean difference (MD) were calculated along with the 95% confidence intervals (CIs). Fourteen trials testing three types of FOSM products (Bailing, Zhiling, and Jinshuibao capsules) involving 1271 participants injected contrast agents were included. For the risk of bias, all trials were rated as some concerns. Compared with routine preventive procedure (RPP) (saline hydration and alprostadil), FOSM products plus RPP showed beneficial effects in reducing the incidence of CA-AKI (14.62% and 5.35%, respectively; RD -0.06, 95% CI -0.09 to -0.03). Subgroup analysis showed that Bailing/Jinshuibao plus RPP demonstrated lower incidence of CA-AKI compared to RPP. However, there was no statistically significant difference between Zhiling with RPP and RPP in the incidence of CA-AKI. Additionally, only when FOSM products were taken before injection of the contrast, it was superior to RPP in reducing the incidence of CA-AKI. There was no statistical difference in adverse events between these two groups. Low certainty evidence suggests that preventive oral use of FOSM products as an adjuvant agent was safe and might decrease the incidence of CA-AKI. However, high-quality placebo-controlled trials are needed to confirm its benefit.
- 8 January 2024
- Published by Taylor & Francis in Renal Failure
- Vol. 46 (1) , 2300302
Open AccessFermented Ophiocordyceps sinensis mycelium products for preventing contrast-associated acute kidney injury: a systematic review of randomized controlled trials
To evaluate the efficacy, effectiveness and safety of fermented Ophiocordyceps sinensis mycelium (FOSM) products for preventing contrast-associated acute kidney injury (CA-AKI). Randomized controlled trials were searched from four Chinese and four English electronic databases and three clinical trial registries up to July 2023. Methodological quality was assessed by using the Cochrane risk-of-bias tool 2.0. Risk difference (RD) or risk ratio (RR) and mean difference (MD) were calculated along with the 95% confidence intervals (CIs). Fourteen trials testing three types of FOSM products (Bailing, Zhiling, and Jinshuibao capsules) involving 1271 participants injected contrast agents were included. For the risk of bias, all trials were rated as some concerns. Compared with routine preventive procedure (RPP) (saline hydration and alprostadil), FOSM products plus RPP showed beneficial effects in reducing the incidence of CA-AKI (14.62% and 5.35%, respectively; RD -0.06, 95% CI -0.09 to -0.03). Subgroup analysis showed that Bailing/Jinshuibao plus RPP demonstrated lower incidence of CA-AKI compared to RPP. However, there was no statistically significant difference between Zhiling with RPP and RPP in the incidence of CA-AKI. Additionally, only when FOSM products were taken before injection of the contrast, it was superior to RPP in reducing the incidence of CA-AKI. There was no statistical difference in adverse events between these two groups. Low certainty evidence suggests that preventive oral use of FOSM products as an adjuvant agent was safe and might decrease the incidence of CA-AKI. However, high-quality placebo-controlled trials are needed to confirm its benefit.
- Open Access
- 21 August 2021
- Published by Elsevier in Integrative Medicine Research
- Vol. 11 (1) , 100772
Compound glycyrrhizin injection for improving liver function in children with acute icteric hepatitis: A systematic review and meta-analysis
- 21 August 2021
- Published by Elsevier in Integrative Medicine Research
- Vol. 11 (1) , 100772
Open AccessCompound glycyrrhizin injection for improving liver function in children with acute icteric hepatitis: A systematic review and meta-analysis
- Open Access
- 1 August 2021
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 60, 102744
Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials
- 1 August 2021
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 60, 102744
Open AccessTherapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials